Misplaced Pages

Bemnifosbuvir

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Bemnifosbuvir
Clinical data
Other namesAT-527, AT-511
Legal status
Legal status
Identifiers
IUPAC name
  • Propan-2-yl (2S)-2--4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC24H33FN7O7P
Molar mass581.542 g·mol
3D model (JSmol)
SMILES
  • C(C(=O)OC(C)C)NP(=O)(OC1(((O1)N2C=NC3=C(N=C(N=C32)N)NC)(C)F)O)OC4=CC=CC=C4
InChI
  • InChI=1S/C24H33FN7O7P/c1-13(2)37-21(34)14(3)31-40(35,39-15-9-7-6-8-10-15)36-11-16-18(33)24(4,25)22(38-16)32-12-28-17-19(27-5)29-23(26)30-20(17)32/h6-10,12-14,16,18,22,33H,11H2,1-5H3,(H,31,35)(H3,26,27,29,30)/t14-,16+,18+,22+,24+,40?/m0/s1
  • Key:OISLSHLAXHALQZ-HEOQURLSSA-N

Bemnifosbuvir (AT-527, RO7496998) is an antiviral drug invented by Atea Pharmaceuticals and licensed to Roche for clinical development, a novel nucleotide analog prodrug originally developed for the treatment of hepatitis C. Bemnifosbuvir is the orally bioavailable hemisulfate salt of AT-511, which is metabolized in several steps to the active nucleotide triphosphate AT-9010, acting as an RNA polymerase inhibitor and thereby interfering with viral replication. Bemnifosbuvir has been researched for the treatment of coronavirus diseases such as that produced by SARS-CoV-2. It showed good results in early clinical trials but had inconsistent results at later stages. Bemnifosbuvir's Phase III study ended early as it failed to meet its primary endpoint of symptom alleviation and did not decrease viral load. However, the drug was well-tolerated and reduced relative hospitalization risk by 71%.

See also

References

  1. Berliba E, Bogus M, Vanhoutte F, Berghmans PJ, Good SS, Moussa A, et al. (September 2019). "Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis". Antimicrobial Agents and Chemotherapy. 63 (12). doi:10.1128/AAC.01201-19. PMC 6879261. PMID 31570394.
  2. Good SS, Moussa A, Zhou XJ, Pietropaolo K, Sommadossi JP (2020). "Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus". PLOS ONE. 15 (1): e0227104. Bibcode:2020PLoSO..1527104G. doi:10.1371/journal.pone.0227104. PMC 6949113. PMID 31914458.
  3. Good SS, Westover J, Jung KH, Zhou XJ, Moussa A, La Colla P, et al. (March 2021). "AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19". Antimicrobial Agents and Chemotherapy. 65 (4). doi:10.1128/AAC.02479-20. PMC 8097421. PMID 33558299.
  4. Lowe D (19 October 2021). "AT-527 Fails a Phase II". In the Pipeline. Science.org.
  5. Fidler B, Gardner J (19 October 2021). "Atea, Roche change plans for oral COVID-19 drug after trial setback". Biopharmadive.com.
  6. Horga A, Saenz R, Yilmaz G, Simón-Campos A, Pietropaolo K, Stubbings WJ, Collinson N, Ishak L, Zrinscak B, Belanger B, Granier C, Lin K, C Hurt A, Zhou XJ, Wildum S, Hammond J (November 2023). "Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY)". Future Virology. 18 (13). doi:10.2217/fvl-2023-0115. PMC 10621114. PMID 37928891.
RNA virus antivirals (primarily J05, also S01AD and D06BB)
Hepatitis C
NS3/4A protease inhibitors (–previr)
NS5A inhibitors (–asvir)
NS5B RNA polymerase inhibitors (–buvir)
Combination drugs
Hepatitis D
Picornavirus
Anti-influenza agents
Multiple/general
Interferon
3CL protease inhibitors (–trelvir)
RNA pol inhibitors
Multiple/Unknown/Other


Stub icon

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: